First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...